Compare CING & BOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CING | BOF |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | 314 |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 60.6M |
| IPO Year | 2021 | 2023 |
| Metric | CING | BOF |
|---|---|---|
| Price | $4.81 | $3.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $34.50 | N/A |
| AVG Volume (30 Days) | ★ 89.2K | 20.4K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.47 | 31.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,184,018.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.20 |
| 52 Week Low | $3.16 | $1.93 |
| 52 Week High | $11.89 | $5.25 |
| Indicator | CING | BOF |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 52.04 |
| Support Level | $4.77 | $3.76 |
| Resistance Level | $5.20 | $3.97 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 7.35 | 68.63 |
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients. The products are mainly sold through three channels: branded retail snack products, private label products for retailers, and fruit and vegetable ingredients sold to food manufacturers.